Friday, August 14, 2026
Facts you can rely on·101 entities·4,772 sourced facts
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 22, 2026

Notable healthcare headlines for the week: J&J, Masimo and Bayer in focus

View original at seekingalpha.com
Notable healthcare headlines for the week: J&J, Masimo and Bayer in focus Wall Street’s major market averages concluded higher on Friday as investors reacted to the latest PCE inflation report, which came in hotter than expected…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Looking to spin off the orthopedics unit

    80% confidence
  • Estimates a ~4.5% growth in diluted non-GAAP EPS excluding tariff-related impact

    80% confidence
  • Continues to project about an $185M headwind from tariffs

    80% confidence
  • Expected 2026 litigation payouts of €5B would cause a cash outflow for the year

    80% confidence
  • The proposed settlement together with a coming U.S. Supreme Court decision on its challenge to the overall merits of the Roundup lawsuits provides a path out of Bayer's litigation uncertainty

    80% confidence
Notable healthcare headlines for the week: J&J, Masimo and Bayer in focus — Source | Via News | Via News